What are the contraindications for sparsentan (which drugs cannot be taken together with it)?

Which drugs should not be taken with sparsentan?

1. Do not use sparsentan (FILSPARI) in combination with ARB, ERA or aliskiren. Combined use of these drugs is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure).

2. Avoid combined use of sparsentan (FILSPARI) with strong CYP3A inhibitors. If strong CYP3A inhibitors cannot be avoided, sparsentan (FILSPARI) treatment should be interrupted. Consider dose titration when resuming FILSPARI therapy.

(FILSPARI), periodically monitor blood pressure, serum potassium, edema, and renal function when used concomitantly with moderate CYP3A inhibitors. No sparsentan dose adjustment is required.

4. Avoid combined use with strong CYP3A inducers. Coadministration with strong CYP3A inducers may decrease the Cmax and AUC of sparsentan, potentially reducing the efficacy of sparsentan.

5. Give sparsentan 2 hours before or 2 hours after antacid administration. Avoid concomitant use of sparsentan with acid-reducing agents (histamine H2 receptor antagonists and PPI proton pump inhibitors). Sparsentan exhibits pH-dependent solubility. Antacids or acid-reducing agents may reduce sparsentan exposure and thus reduce sparsentan's efficacy.

6. Monitor for signs of worsening renal function during concomitant use of NSAIDs, including selective COX-2 inhibitors. In patients who are volume-depleted (including those receiving diuretics) or with compromised renal function, the concomitant use of NSAIDs, including selective COX-2 inhibitors, with drugs that antagonize angiotensin II receptors may result in worsening of renal function, including possible renal failure. However, these effects are usually reversible.

7. Avoid the combined use of P-gp and BCRP sensitive substrates with FILSPARI. Sparsentan is an inhibitor of P-gp and BCRP. Sparsentan may increase exposure to these transporter substrates, which may increase the risks associated with these substrates.

8. Serum potassium should be monitored frequently in patients receiving Sparsentan and other drugs that may increase serum potassium. Concomitant use of Sparsentan with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, or other drugs that increase serum potassium levels may result in hyperkalemia.

The above are the contraindications for the use of sparsentan. For more details, please refer to the drug instructions. It is recommended that patients follow the doctor's instructions and treat symptoms, and inform the attending doctor of the drugs they are taking before taking the drug.

Recommended related articles: